NBIX · Neurocrine Biosciences Inc · Executive Compensation

$148.45 +2.45 (+1.68%) Q2 2026 earnings call transcript

S&P 400 member Russell 1000 member Rebalance outlook locked

Market Cap

$14.84B

101.65M

Volume · Oct 28 1.09M Avg daily vol (3M) 1.31M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kyle W. Gano	Chief Executive Officer	$920,000	$966,000	$5,750,023	$5,750,006	—	$62,906	$13,448,935
Sanjay Keswani	Chief Medical Officer	$379,167	$488,000	$4,000,120	$3,999,963	—	$140,553	$9,007,803
Jude Onyia	Chief Scientific Officer	$720,520	$645,000	$2,999,925	$3,000,011	—	$45,313	$7,410,769
Matthew C. Abernethy	Chief Financial Officer	$725,913	$526,000	$2,499,918	$2,500,036	—	$60,045	$6,311,912
Strategic Advisor	—	$731,400	$530,000	$2,375,004	$2,375,029	—	$61,599	$6,073,032
Eric Benevich	Chief Commercial Officer	$668,690	$463,000	$2,349,928	$2,349,995	—	$57,334	$5,888,947

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin C. Gorman	Former Chief Executive Officer	$779,357	$1,141,950	$7,000,139	$6,999,698	—	$97,493	$16,018,637
Kevin Gorman	CEO	$779,357	$1,141,950	$7,000,139	$6,999,698	—	$97,493	$16,018,637
Kyle W. Gano	Chief Executive Officer	$698,217	$536,906	$3,700,106	$3,549,970	—	$50,223	$8,535,422
Jude Onyia	Chief Scientific Officer	$676,545	$505,717	$2,440,182	$3,359,848	—	$53,559	$7,035,851
Eiry Roberts	Chief Medical Officer	$686,761	$513,354	$2,350,087	$3,150,017	—	$64,099	$6,764,318
Strategic Advisor	—	$686,761	$513,354	$2,350,087	$3,150,017	—	$64,099	$6,764,318
Matthew C. Abernethy	Chief Financial Officer	$684,824	$452,840	$2,599,987	$2,799,904	—	$57,646	$6,595,201
Eric Benevich	Chief Commercial Officer	$636,848	$366,188	$2,800,081	$2,449,932	—	$53,115	$6,306,164

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin C. Gorman	Former Chief Executive Officer	$946,000	$1,040,600	$7,021,386	$6,678,790	—	$64,036	$15,750,812
Kevin Gorman	CEO	$946,000	$1,040,600	$7,021,386	$6,678,790	—	$64,036	$15,750,812
Jude Onyia	Chief Scientific Officer	$638,250	$351,038	$2,625,124	$3,375,024	—	$233,780	$7,223,216
Matthew C. Abernethy	Chief Financial Officer	$646,061	$355,335	$1,812,563	$3,187,536	—	$56,387	$6,057,882
Kyle W. Gano	Chief Executive Officer	$602,912	$331,602	$1,812,563	$3,187,536	—	$55,602	$5,990,215
Eiry Roberts	Chief Medical Officer	$660,348	$399,511	$2,125,112	$2,625,024	—	$63,852	$5,873,847

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Gorman	CEO	$860,000	$989,000	$5,125,079	$4,875,106	—	$53,342	$11,902,527
Kevin C. Gorman	Former Chief Executive Officer	$860,000	$989,000	$5,125,079	$4,875,106	—	$53,342	$11,902,527
Eiry Roberts	Chief Medical Officer	$631,912	$345,182	$2,075,144	$2,625,057	—	$57,986	$5,735,281
Kyle W. Gano	Chief Executive Officer	$550,605	$332,428	$1,725,086	$2,775,053	—	$38,485	$5,421,657
Matthew C. Abernethy	Chief Financial Officer	$618,240	$373,262	$1,570,128	$2,310,061	—	$52,632	$4,924,323
Darin M. Lippoldt	Chief Legal Officer	$548,730	$315,520	$1,550,136	$2,250,049	—	$56,761	$4,721,196
Jude Onyia	Chief Scientific Officer	$575,000	$330,625	$1,275,146	$225,008	—	$55,520	$2,461,299

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin C. Gorman	Chief Executive Officer	$825,000	$701,250	$6,406,366	$6,093,752	—	$55,044	$14,081,412
Kevin Gorman	CEO	$825,000	$701,250	$6,406,366	$6,093,752	—	$55,044	$14,081,412
Jude Onyia	Chief Scientific Officer	$52,340	$26,170	$3,000,136	$4,500,035	—	$2,949	$7,581,630
Eiry Roberts	Chief Medical Officer	$604,700	$272,115	$2,875,113	$2,625,019	—	$48,649	$6,425,596
Matthew C. Abernethy	Chief Financial Officer	$588,800	$264,960	$2,375,068	$2,625,019	—	$53,003	$5,906,850
Kyle W. Gano	Chief Business Development and Strategy Officer	$517,000	$271,425	$2,375,067	$2,625,018	—	$22,814	$5,811,324
Eric Benevich	Chief Commercial Officer	$534,900	$213,960	$2,375,068	$2,625,019	—	$56,139	$5,805,086
Darin M. Lippoldt	Chief Legal Officer	$525,100	$262,550	$2,312,606	$2,437,544	—	$52,361	$5,590,161

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin C. Gorman	Chief Executive Officer	$775,000	$542,500	$5,375,188	$7,124,633	—	$63,311	$13,880,632
Kevin Gorman	CEO	$775,000	$542,500	$5,375,188	$7,124,633	—	$63,311	$13,880,632
Kyle W. Gano	Chief Business Development and Strategy Officer	$487,700	$207,273	$2,750,208	$3,750,008	—	$16,751	$7,211,940
Eric Benevich	Chief Commercial Officer	$499,900	$199,960	$3,000,257	$2,999,869	—	$48,974	$6,748,960
Matthew C. Abernethy	Chief Financial Officer	$545,200	$190,820	$2,500,266	$2,999,869	—	$45,021	$6,281,176
Eiry Roberts	Chief Medical Officer	$575,900	$215,963	$2,375,242	$2,624,855	—	$56,073	$5,848,033
Darin M. Lippoldt	Chief Legal Officer	$486,200	$170,170	$2,312,780	$2,437,508	—	$45,704	$5,452,362

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Gorman	CEO	$725,000	$667,000	$2,000,071	$6,000,525	—	$58,230	$9,450,826
Kevin C. Gorman	Chief Executive Officer	$725,000	$667,000	$2,000,071	$6,000,525	—	$58,230	$9,450,826
Matthew C. Abernethy	Chief Financial Officer	$495,600	$284,970	$1,250,035	$3,750,345	—	$42,170	$5,823,120
Eric Benevich	Chief Commercial Officer	$467,200	$280,320	$1,250,035	$3,750,345	—	$45,547	$5,793,447
Eiry Roberts	Chief Medical Officer	$538,200	$309,465	$1,000,076	$3,000,285	—	$51,889	$4,899,915
Haig P. Bozigian	Chief Development Officer	$461,500	$265,363	$1,000,076	$3,000,285	—	$53,772	$4,780,996
Kyle W. Gano	Chief Development and Strategy Officer	$443,400	$266,040	$1,000,076	$3,000,285	—	$16,171	$4,725,972

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Gorman	CEO	$675,000	$425,250	$2,998,832	$4,486,852	—	$47,045	$8,632,979
Kevin C. Gorman	Chief Executive Officer	$675,000	$425,250	$2,998,832	$4,486,852	—	$47,045	$8,632,979
Eiry Roberts	Chief Medical Officer	$490,700	$220,800	$4,053,869	$2,863,700	—	$671,554	$8,300,623
Kyle W. Gano	Chief Development and Strategy Officer	$403,100	$191,473	$2,656,575	$1,309,024	—	$8,069	$4,568,241
Eric Benevich	Chief Commercial Officer	$432,600	$205,485	$1,499,417	$1,496,335	—	$38,768	$3,672,605
Haig P. Bozigian	Chief Development Officer	$439,500	$197,775	$1,003,685	$1,309,024	—	$43,822	$2,993,806
Matthew C. Abernethy	Chief Financial Officer	$420,000	$199,500	$1,996,506	—	—	$69,741	$2,685,747

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Kevin Gorman	CEO	$640,000	$515,200	$1,426,920	$4,929,898	—	$44,356	$7,556,374
Kevin C. Gorman	Chief Executive Officer	$640,000	$515,200	$1,426,920	$4,929,898	—	$44,356	$7,556,374
Matthew C. Abernethy	Chief Financial Officer	$38,231	$20,071	$920,000	$2,416,800	—	$394,190	$3,789,292
Eric Benevich	Chief Commercial Officer	$410,000	$246,000	$458,344	$1,825,536	—	$37,722	$2,977,602
Haig P. Bozigian	Chief Development Officer	$408,800	$235,060	$458,344	$1,825,536	—	$41,694	$2,969,434

Executive changes

Person	Role	Change	Effective	Filed
Sanjay Keswani, M.D.	Chief Medical Officer	Terminated	2026-09-25	2026-09-28
Eiry W. Roberts, M.D.	Chief Medical Officer	Appointed	2026-09-28	2026-09-28
Johanna Mercier	Class III Director	Appointed	2026-05-27	2026-05-28
Gary A. Lyons	Class III Director	Appointed	2026-05-27	2026-05-28
Kevin C. Gorman, Ph.D.	Class III Director	Appointed	2026-05-27	2026-05-28
Sanjay Keswani, M.D.	Chief Medical Officer	Appointed	2025-06-02	2025-05-30
Shalini Sharp	Class II Director	Appointed	2025-05-21	2025-05-22
Stephen A. Sherwin, M.D.	Class II Director	Appointed	2025-05-21	2025-05-22
Richard F. Pops	Class II Director	Appointed	2025-05-21	2025-05-22
Kyle W. Gano, Ph.D.	Class II Director	Appointed	2025-05-21	2025-05-22
Sanjay Keswani, M.D.	Chief Medical Officer	Appointed	2025-06-02	2025-04-04
Kyle Gano, Ph.D.	President and Chief Executive Officer	Appointed	2024-10-11	2024-10-11
Kyle Gano, Ph.D.	President and Chief Executive Officer	Appointed	2024-10-11	2024-05-28
Kyle Gano, Ph.D.	Class II director	Appointed	2024-10-11	2024-05-28
Kevin C. Gorman, Ph.D.	President and Chief Executive Officer	Retired	2024-10-11	2024-05-28
Leslie V. Norwalk	Class I Director	Appointed	2024-05-22	2024-05-23
Christine A. Poon	Class I Director	Appointed	2024-05-22	2024-05-23
George J. Morrow	Class I Director	Appointed	2024-05-22	2024-05-23
William H. Rastetter, Ph.D.	Class I Director	Appointed	2024-05-22	2024-05-23
Christine A. Poon	member of the Board	Appointed	2023-07-11	2023-07-12
Johanna Mercier	Class III Director	Appointed	2023-05-17	2023-05-19
Gary A. Lyons	Class III Director	Appointed	2023-05-17	2023-05-19
Kevin C. Gorman, Ph.D.	Class III Director	Appointed	2023-05-17	2023-05-19

Leadership

Kevin Gorman CEO, Board Member
Kyle Gano, Ph.D. CEO, Board Member
Kyle W. Gano CEO, Board Member
Matthew C. Abernethy CFO
Christine A. Poon Board Member
Gary A. Lyons Board Member
George J. Morrow Board Member
Johanna Mercier Board Member
Kevin C. Gorman Board Member
Kevin C. Gorman, Ph.D. Board Member
Kyle W. Gano, Ph.D. Board Member
Leslie V. Norwalk Board Member
Richard F. Pops Board Member
Shalini Sharp Board Member
Stephen A. Sherwin Board Member
Stephen A. Sherwin, M.D. Board Member
William H. Rastetter Board Member
William H. Rastetter, Ph.D. Board Member

Key facts CIK 914475 CUSIP 64125C109 13F (30d) 195 filings 184 filers Visit website Investor relations